Alle Storys
Folgen
Keine Story von Gerresheimer AG mehr verpassen.

Gerresheimer AG

New Focus in Project Portfolio of Gerresheimer Subsidiary Sensile Medical

Germany (ots/PRNewswire)

- SQ Innovation and Gerresheimer sign partnership for micro pumps for heart failure treatment

- Sanofi terminates development project for micro pumps for patients with diabetes

- Further projects with pharma customers for various therapy areas for the micro pump started

Sensile Medical, a subsidiary of Gerresheimer AG, has signed a contract with the Swiss biopharma­ceutical company SQ Innovation AG for the development, market launch and mass production of a micro pump for the treatment of edema in heart failure. Sanofi, on the other hand, has terminated the project with Sensile Medical to develop a micro pump for delivery of insulin to treat diabetes.

"Our micro pump technology is highly advanced and very competitive. It can be used for a variety of treatments across medical conditions. The new SQ Innovation agreement illustrates the attractiveness of our micro pump technology. The pipeline of projects for the micro pump is very promising and we continue to see significant potential in this unique technology," said Dietmar Siemssen, CEO of Gerresheimer AG.

Sensile Medical, a Gerresheimer company, and SQ Innovation AG signed a partnership for the micro pump for the treatment of edema in heart failure for European and American markets. The market launch of the SQ Innovation product is to take place after completion of development and obtaining market authorization. Sensile Medical's micro pump for Parkin­son's treatment has already been approved for the European market in September 2018 and has been launched. A different project, the micro pump for delivery of insulin to treat diabetes, has been terminated by Sanofi for strategic reasons.

Gerresheimer has started several projects with pharma customers for usage of the micro pump in various therapy areas, which illustrate the future potential.

Information about SQ Innovation AG: http://furosemide.com

Gerresheimer AG 
Klaus-Bungert-Strasse 4 
40468 Düsseldorf 
Germany
Contact: 
Jens Kürten 
Group Senior Director Communication & Marketing 
Phone: +49-211-6181-250 
Telefax: +49-211-6181-241  
jens.kuerten@gerresheimer.com  
www.gerresheimer.com

Weitere Storys: Gerresheimer AG
Weitere Storys: Gerresheimer AG
  • 11.07.2019 – 08:10

    Gerresheimer Reports Strong Second Quarter

    - Revenues up 7.2% on the prior-year quarter to EUR 356.5m - Adjusted EBITDA at EUR 74.2m in second quarter of 2019 (Q2 2018: EUR 71.1m), excluding EUR 26.2m from derecognition of contingent purchase price compo­nents in connection with Sensile Medical acquisition - Revenue guidance confirmed without change; guidance on adjusted EBITDA at constant exchange rates for the financial year 2019 approximately EUR 295m (plus ...

  • 14.05.2019 – 10:31

    Dr. Bernd Metzner to Become Chief Financial Officer of Gerresheimer AG on May 15, 2019

    Duesseldorf, Germany (ots/PRNewswire) - Dr. Bernd Metzner (48) takes up the position of Chief Financial Officer of Gerresheimer AG on May 15, 2019. Dr. Metzner had been Chief Financial Officer of SDAX-listed Ströer SE & Co. KGaA since 2014. "I very much welcome the financial expertise and years of industry experience that Dr. Bernd Metzner brings to the Management ...

  • 11.10.2018 – 08:05

    Gerresheimer Increases Revenues by 8.8% and Successfully Integrates Sensile Medical

    Düsseldorf, Germany (ots/PRNewswire) - - Revenues at constant exchange rates up 8.8% in third quarter of 2018 to EUR 364.4m - Adjusted EBITDA at constant exchange rates-excluding Sensile Medical and negative effects relating to the exemption from electricity network charges-increased by EUR 1.3m in third quarter to EUR 79.5m - Integration of Sensile Medical proceeding ...